Welcome to our dedicated page for Larimar Therapeutics news (Ticker: LRMR), a resource for investors and traders seeking the latest updates and insights on Larimar Therapeutics stock.
Larimar Therapeutics, Inc. develops treatments for complex rare diseases, with its lead program, nomlabofusp, focused on Friedreich’s ataxia. Nomlabofusp is a subcutaneously administered recombinant fusion protein designed to deliver frataxin to mitochondria, and company updates frequently address clinical data, frataxin measurement, FDA interactions and regulatory designations tied to that program.
Recurring LRMR news also covers operating and financial results, equity financing activity, corporate presentations and research publications related to its intracellular delivery platform. The company’s disclosures connect program development with capital needs, rare-disease regulatory pathways and the broader use of fusion proteins for diseases involving intracellular bioactive-compound deficiencies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Lariamar Therapeutics (Nasdaq: LRMR) announced its participation in the Guggenheim Genomic Medicines and Rare Disease Days on April 3-4, 2023. The company will engage in a virtual fireside chat and 1x1 investor meetings, showcasing its focus on developing treatments for complex rare diseases.
The fireside chat is scheduled for April 4, 2023, at 4:35 PM ET, accessible via a live webcast link. Following the event, a replay will be available on Larimar's Events and Presentations page. Larimar Therapeutics is advancing its lead compound, CTI-1601, for Friedreich's ataxia and aims to create further treatments for rare diseases through its innovative platform.
Lakimar Therapeutics reported key updates on its Phase 2 trial of CTI-1601 for Friedreich's ataxia, with the first cohort fully enrolled as of March 14, 2023. The company expects to announce the next steps following an FDA review in Q2 2023. As of December 31, 2022, Larimar held cash and investments totaling $118.4 million, projecting a runway into 2H 2024. For Q4 2022, the net loss was $9.4 million (or $0.21 per share), an increase from the previous year. Total net loss for 2022 was $35.4 million, down from $50.6 million in 2021, indicating improved financial health amidst ongoing R&D investments.